

Antioxidant effect of sodium selenite on thioacetamide-induced renal toxicity

Qudsia Begum*, Shafaq Noori and Tabassum Mahboob
Department of Biochemistry, University of Karachi, Karachi, Pakistan

Abstract: Thioacetamide is an organosulfur compound and reasonably anticipated to be a human carcinogenic and toxic effect. Sodium selenite is considered to be an anticarcinogenic and antioxidant, therefore, the aim of study is to evaluate the toxic effect of thioacetamide and the role of sodium selenite on renal tissues by using rat model. 24 Albino wistar rats of male sex (b.w: 200±30gm) were divided into four groups (n = 6). Group I control (un treated), Group II received thioacetamide (200mg/kg b.w; i.p.) for 12 weeks; twice in a week, Group III received sodium selenite (1mg/kg b.w; i.p.) for 12 week; thrice in a week and Group IV received sodium selenite (1mg/kg: thrice in a week)+thioacetamide (200mg/kg: twice in a week) for 12 weeks (sodium selenite was given 30 minute prior to thioacetamide administration). Thioacetamide mediated toxic effects are measured in terms of renal functions; creatinine and urea, oxidative stress; MDA and antioxidant status; SOD, GSH and catalase levels. The significant increase in urea level and decrease GSH and MDA level in thioacetamide treated group was observed. Sodium selenite treatment restored the glutathione level in thioacetamide+sodium selenite treated group. The results describe decreased MDA levels which show the toxic effect of thioacetamide on renal tissues while the sodium selenite did not over come this toxic effect but explain its antioxidant property by increasing the GSH level in renal tissues.

Keywords: Antioxidant, sodium selenite, thioacetamide, renal toxicity.

Received: December 8, 2010 **Accepted:** February 12, 2011

***Author for Correspondence:** qudsiahameed93@hotmail.com

INTRODUCTION

Thioacetamide is an organosulphur compound that is known to be a carcinogenic¹. Toxicity of thioamide in mammals and *Mycobacterium* spp. is dependent on metabolic activation of the compounds via sequential oxygenations of the thioamide sulfur atom by flavoprotein mono-oxygenases or cytochromes P450². Free radical formation is postulated with various compounds including thioacetamide³. Aerobic forms of life have enzymatic antioxidant defenses; superoxide dismutase (SOD), glutathione peroxidase (GSH) and catalase. These enzymatic antioxidants operate in tandem to decompose free radicals. SOD is the known enzyme whose substrate is only free radicals⁴ unlike GSH which acts on peroxides from various sources⁵.

There is a balance between ROS production and its scavenger system within the cells to prevent or minimize free radicals damage, including enzymatic and non-enzymatic mechanisms. Selenium is an antioxidant and a trace element, which is incorporated into the catalytic site of antioxidant enzymes, such as GSH, and is involved in cell growth and development by protecting cells against the toxic and damaging effects of ROS⁶⁻⁹.

The biological importance of selenium is at least 3-fold. First, it forms the prosthetic group of some critical selenocysteine-containing enzymes, such as glutathione peroxidase, iodothyronine 5'-deiodinase, and thioredoxin reductase¹⁰. Second, sodium selenite is protective against a number of toxicants. Third, selenium excessive intake cause toxic potential¹¹. Sodium selenite as an exogenous source of selenium

is used for endogenous selenoprotein synthesis to scavenge the free radicals¹². Because selenium is an essential element, sodium selenite is an ingredient in some food supplements¹³. The mode of action of selenium is unknown but may involve antioxidant defense mechanisms¹⁴.

The kidney is highly susceptible to toxicants for two reasons. A high volume of blood flows through it and it filters large amounts of toxins which can concentrate in the kidney tubules. It can result in systemic toxicity causing: decreased ability to excrete body wastes, inability to maintain body fluid and electrolyte balance and decreased synthesis of essential hormones¹⁵.

The aim of present study is to evaluate the protective role of sodium selenite against the thioacetamide induced renal and oxidative stress in rats using an experimental rat model, the present study describes plasma nitrate and renal tissue MDA levels, renal tissue enzymes SOD and catalase and plasma urea and creatinine in order to analyze antioxidant status in thioacetamide treated rats after pretreatment with sodium selenite.

MATERIALS AND METHODS

Animals and diet

Albino wistar rats of male sex (200±30 g b.w.), purchased from the animal house of ICCBS, (Karachi, Pakistan) were used for the study. Animals were acclimatized to the laboratory conditions one week before the start of experiment and caged in a quite temperature controlled room (23±4°C). Rats had free access to water and standard rat diet.

Study design

The animals were divided into four experimental groups; each consisting of six rats and received following treatments:

Group I: Control group, untreated.

Group II: Received thioacetamide (200mg/kg b.w; i.p.) for 12 weeks; twice in a week.

Group III: Received sodium selenite (1mg/kg b.w; i.p.) for 12 weeks; thrice in a week.

Group IV: Received thioacetamide+sodium selenite.

Sample collection

After 48 hours of last dose of treated groups, animals were decapitated and blood was sampled from head wound in the lithium heparin coated tubes. A portion of blood was used to collect plasma. Kidneys were excised, trimmed of connective tissues, rinsed with saline to eliminate blood contamination, dried by blotting with filter paper and weighed. The tissues then kept in freezer -70 °C until analyses.

Preparation of kidney homogenate

Kidney homogenates were obtained by using a tissue homogenizer, ultra taurax T-25 polytron, at 4°C. The homogenates (1:10 w/v) were prepared by using a 100m mol KCl buffer (pH: 7) containing EDTA 0.3 m mol. All homogenates were centrifuge at 600 g for 60 minutes at 4 °C and the supernatant marked as “sample” and used for biochemical assays.

Assessment of renal functions

Plasma samples were assayed for urea & creatinine. Urea was estimated by the monoxime method¹⁶. Creatinine was estimated by the Jeff's method¹⁷.

Assessment of oxidative stress

The malonyldialdehyde (MDA) content, a measure of lipid peroxidation, was assayed in the form of thiobarbituric acid reacting substances (TBARS) by Ohkawa et al., 1979 by using tissue homogenates¹⁸.

Assessment of antioxidant status

Levels of SOD in the cell free supernatant were measured by the previously described method¹⁹. GSH level were measured by the method described earlier²⁰. Catalase activity was assayed by the method of²¹.

Statistical analysis

Results are expressed as mean±SD. Statistical significance and difference from control and test values evaluated by Student's t-test. Statistical probability of *P<0.05, **P<0.01, ***P<0.001 were considered to be significant. +P< 0.005, ++P<0.01, +++P<0.001 were significant in comparison of thioacetamide (alone) group with thioacetamide and

sodium selenite (combination) group. ns represent non significant result.

RESULTS

Body weight was significantly decreased in thioacetamide group (215.33±53.12, P<0.01) as compare to control. Treatment with sodium selenite increases the body weight nonsignificantly (246.125±53.12), while increased significantly in sodium selenite+thioacetamide treated group (366.33±14.57) compared with control (P<0.01) and with thioacetamide group (P<0.01) (Figure 1). Urea levels in thioacetamide and sodium selenite treated groups significantly increased (P<0.05 and P<0.001) respectively and increased nonsignificantly in sodium selenite+thioacetamide treated group (P<0.05) as compared to control. While nonsignificantly decreased in sodium selenite+thioacetamide treated group as compared with thioacetamide group (Figure 2a). Creatinine levels increased nonsignificantly in thioacetamide treated group. While levels of creatinine decreased in sodium selenite and sodium selenite+thioacetamide treated group (P<0.05) as compared to control (Figure 2b).

Table 1: Effect on body weight, kidney weight & relative kidney weight in control, TAA, SS and SS+TAA group.

Parameters (g)	Control	Thioacetamide (TAA)	Sodium Selenite (SS)	SS+TAA
Kidney Weight	0.294±0.043	0.302±0.046	0.404±0.024	0.441±0.069
Relative Kidney Weight10 ⁻³	1.29±0.184	1.401±0.222	2.013±0.712	1.203±0.183


Values are mean±SD.

Significant difference between control, thioacetamide, sodium selenite and sodium selenite+thioacetamide treated rats was *p<0.05.

MDA levels in thioacetamide, sodium selenite and thioacetamide+sodium selenite treated groups were significantly decreased (P<0.05) as compared to control (Figure 3).



SOD levels significantly decreased in sodium selenite (P<0.001) and sodium selenite+thioacetamide treated group (P<0.01) as compared to control. The SOD levels significantly decreased in sodium selenite+thioacetamide treated group (P<0.01) as compared to thioacetamide group (Figure 4a). Significantly decreased GSH levels were observed in thioacetamide treated group (P<0.01). GSH significantly increased in sodium selenite treated group (P<0.01) as compared to control. The GSH level significantly increased in sodium selenite+thioacetamide treated group (P<0.05) as compared to Thioacetamide group (Figure 4b).

Figure 1: Effect of sodium selenite and thioacetamide on body weight



Values are mean±SD. Significant difference between control, thioacetamide, sodium selenite and sodium selenite+thioacetamide treated rats was *P<0.05 and ***P<0.001.

Figure 2: Effect of sodium selenite and thioacetamide on renal functions (a) urea (b) creatinine




Values are mean±SD. Significant difference between control, thioacetamide, sodium selenite and sodium selenite+thioacetamide treated rats was *P<0.05 and ***P<0.001.

Catalase activity was increased nonsignificantly in thioacetamide treated group as compared to control while significantly decreased in sodium selenite and sodium selenite+thioacetamide treated

group (P<0.05). The sodium selenite+thioacetamide group were also decreased catalase activity (P<0.05) when compare with thioacetamide treated group (Figure 4c).

Figure 3: Effect of sodium selenite and thioacetamide on oxidative stress (MDA).



Values are mean±SD. Significant difference between control, thioacetamide, sodium selenite and sodium selenite+thioacetamide treated rats was **p<0.01.


DISCUSSION

Thioacetamide is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals. Thioacetamide given orally to rats produces centrolobular hepatic necrosis and also causes death of the cells in the terminal portion of the proximal renal tubule¹.

In the present study TAA administration (200mg/kg) to rats for 12 weeks has been observed to cause renal toxicity as assessed biochemical parameters these were renal function (urea and creatinine), oxidative stress (MDA) and antioxidant status (SOD, GSH and Catalase). Free radicals are believed to play a major role in the development of TAA-induced toxicity²². Exacerbation of lipid peroxidation and depletion of antioxidants have been reported by various investigators^{23,24}. Indeed in the present study the prooxidant-antioxidant balance has been observed to change of oxidation, as also found in the previous study²⁵. TAA administration results in increased urea and creatinine levels (Figure: 4a and b). The increased levels of urea and creatinine show insufficiency of renal function. Studies in animals have established that tubular injury plays a central role in the reduction of glomerular filtration rate in acute tubular necrosis. Two major tubular abnormalities could be involved in the decrease in glomerular function in TAA treated rats: obstruction and back leak of glomerular filtrate. The alterations

in glomerular function in TAA treated rats may also be secondary to ROS (reactive oxygen species) as described earlier²⁶ which induce mesangial cells contraction, altering the filtration surface area and modifying the ultrafiltration coefficient factors that decrease the glomerular filtration rate²⁷.

Figure 4: Effect of sodium selenite and thioacetamide on antioxidant status: (a) SOD (b) GSH and (c) Catalase Levels.



Values are mean±SD.

Significant difference between control, thioacetamide, sodium selenite and sodium selenite+thioacetamide treated rats was * $p < 0.05$.

Decreased antioxidant enzymes levels (SOD, GSH) were observed in the present study after thioacetamide administration (Figure: 4a and b). Decreased SOD level ($p < 0.001$) may indicate an imbalance in free radical levels and hence increase in

cellular damage. There is an imbalance between the amount of free radicals generated and the antioxidant present in the cell in favor of the oxidation. As the toxicity produce SOD was not synthesized by cells hence, present in low amount²⁸. The significant decrease of GSH level observed in thioacetamide treated group ($p < 0.01$). GSH is a scavenger of hydroxyl radicals and singlet oxygen. It is capable of either directly scavenging free radicals or enzymatically via glutathione peroxidase. In addition, GSH is crucial to the maintenance of enzymes and other cellular components in a reduced state²⁹. Decreased level of GSH during the present study indicates that toxic effect is produced by thioacetamide in renal tissues.

There is increased in catalase activity in thioacetamide treated group as compared to control ($p < 0.05$) (Figure 4c) which indicates increased antioxidant status. Catalase and glutathione peroxidase seek out hydrogen peroxide and convert it to water and diatomic oxygen. An increase in the production of SOD without a subsequent elevation of catalase leads to the accumulation of hydrogen peroxide, which gets converted into the hydroxyl radical. Low level of the activity of total antioxidant status, SOD and GSH indicate the distortion of oxidant-antioxidant balance and decreased organism antioxidant system efficiency²⁹.

Although the exact mechanism of thioacetamide induced nephrotoxicity is not well understood, several studies suggested the involvement of free radicals. Oxidative stress develops when the disturbances between reactive oxygen forms are produced in excess and the factors preventing their harmful effect occur³⁰.

Thioacetamide induced nephrotoxicity is associated with decrease level of MDA ($p < 0.01$) (Figure 4). MDA is the end product of ω_3 and ω_6 polyunsaturated fatty acids produced by decomposition³¹. Due to thioacetamide administration, thioamide S,S-dioxides formed via sequential oxygenations of the thioamide sulfur atom by flavoprotein monoxygenases or cytochrome P450³², which have not been isolated or further oxidized species exert the observed toxic effects. This activity results in elimination of the thioamide sulfur and formation of nitrile or amide derivatives³³, by renal cells and stabilized by intracellular GSH for several hours. In case of intracellular GSH depletion the complexes undergo the rapid transformation to receive metabolites. This depletion seems to be the prime factor that permits lipid peroxidation and impair antioxidant enzymes²⁷.

Nephroprotection by the exogenous selenite might be directly related to its antioxidant activity.

Selenite, an important exogenous source for endogenous selenium compounds, is known to be extensively biotransformed³⁴. It undergoes glutathione (GSH)-dependent reductions to form, consecutively, GS-Se-SG, GS-SeH, and hydrogen selenide (HSeH). The last is methylated sequentially, resulting in production of methylselenol (CH₃SeH), then the volatile and exspirable dimethyl selenide (CH₃SeCH₃), and finally trimethylselenonium ion [(CH₃)₃Se⁺], which is excreted in urine. Selenide is also the precursor for selenocysteine and thus is needed for synthesis of selenoproteins. Additionally, selenide is also a toxic metabolite of selenite²⁷, whereas methylselenol is thought to be involved in both toxicity and anticarcinogenic activity³¹ of selenite and it proved by increased urea levels and decreased creatinine levels after administration of sodium selenite (1mg/kg) in present study.

In present study, decreased SOD and catalase levels observed in sodium selenite treated group. Which represent that SOD and Catalase act as a cellular defense element against potentially harmful effects of superoxide ions by catalyzing the dismutation of these ions²⁸.

Our results demonstrate that counter effect of sodium selenite not overcome the thioacetamide - induce renal toxicity but showed no significant result with MDA. Elevated levels of GSH in this study exhibited the antioxidant property of sodium selenite³⁵.

REFERENCES

- Edward AB, and Edward AS. Nonhepatic Thioacetamide Injury: II. The Morphologic Features of Proximal Renal Tubular Injury. *Am. J. Pathol.*, 1974; 74: 575-590.
- Debarber AE, Mdluli K, Bosman M, Bekker LG and Barry CE. Ethionamide Activation and Sensitivity in Multidrug-Resistant Mycobacterium tuberculosis. *Proc. Natl. Acad. Sci., USA*, 2000; 97: 9677-9682.
- Buko V, Lukivskaya O, Nikitin V, Kuryan A and Dargel R. Antioxidative effect of prostaglandin E2 in thioacetamide induced liver cirrhosis. *Exp. Toxicol. Pathol.*, 1997; 49: 141-146.
- Cheeseman KH and Slater TF. Free radicals in medicine. *Br. Med. Bull.*, 1993; 49: 489.
- Murray RK, Granner DK, Mayes PA and Rodwell VW. Harper's Biochemistry, In: Murray RK editors. Red and white blood cells. 25th ed. McGraw-Hill, 1999; 767.
- Yoon SO, Kim MM, Park SJ, Kim D, Chung J and Chung AS. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. *FASEB J.*, 2002; 16: 111-113.
- Patrick L. Selenium biochemistry and cancer: a review of the literature. *Altern. Med. Rev.*, 2004; 9: 239-258.
- Papp LV, Lu J, Holmgren A and Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. *Antioxid. Redox Signal*, 2007; 9: 775-806.
- Abedelahi A, Salehnia M and Allameh A. The effects of different concentrations of sodium selenite on the in vitro maturation of preantral follicles in serum-free and serum supplemented media. *J. Assist. Reprod. Genet.*, 2008; 25: 483488.
- Stadtman TC. Selenocysteine. *Ann. Rev. Biochem.*, 1996; 65: 83-100.
- Combs GF and Gray WP. Chemopreventive agents: Selenium. *Pharma. Ther.*, 1998; 79: 179-192.
- Wilber CG. Toxicology of selenium. *Clinical Toxicology*, 1980; 17:171-230.
- Schrauzer GN. Nutritional selenium supplements: product types, quality, and safety. *J. Am. Coll. Nutr.*, 2001; 20: 1-4.
- Al-Bader AH, Hussain T, Al-Moosauti M, Mathew TC and Dashti H. Selenium and liver cirrhosis. *Mol. Cell. Biochem.*, 1998; 185-186
- Oduola T, Bello I, Adeosun G, Abdul-Waheed A, Raheem G and Avwioro G. Hepatotoxicity and nephrotoxicity evaluation in Wistar albino rats exposed to Morinda lucida leaf extract. *North Am. J. Med. Sci.*, 2010; 2: 230-233.
- Ather MA and Ronald D. The automated thiosemicarbazide-diacetylene monoxime method for plasma urea. *Clin. Chem.*, 1969; 97: 16393-16396.
- Spierto FW, Macneil ML and Burtis CA. The effect of temperature and wavelength on the measurement of creatinine with the jaffe's procedure. *Clin. Biochem.*, 1979; 12: 18-21.
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Ann. Biochem.*, 1979; 95: 351-358.
- Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay for superoxide dismutase. *Arch. Biochem. Biophys.*, 1978; 186: 189-195.
- Calberg and Mannervik B. Gluta thione Reductase. *Methods. Enzymology*, 1985; 113: 484-490.
- Sinha KA. Colorimetric assay of catalase. *Anal. Biochem.*, 1972; 47: 389-394.
- Abul H, Mathew TC, Dashti HM and Al-Bader A. Level of superoxide dismutase, glutathione peroxidase and uric acid in thioacetamide-induced cirrhotic rats. *Anat. Histol. Embryol.*, 2002; 31:66-71.
- Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O and Tsunematsu S. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. *J. Gastroenterol. Hepatol.*, 2008; 23: 1909-1916.
- Cruz A, Padillo FJ, Torres E, Navarrete CM, Munoz-Castaneda JR and Caballero FJ. Melatonin prevents experimental liver cirrhosis induced by thioacetamide in rats. *J. Pineal. Res.*, 2005; 39:143-150.
- Balkan J, Dogru-Abbasoglu S, KanbagliO, Cevikbas U Aykac Toker G and Uysal M. Taurine has protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. *Hum. Exp. Toxicol.*, 2001; 20: 251-254.
- Leena P and Alaraman BR. Effect of green tea extract on cisplatin induced oxidative damage on kidney and testes of rats. *Ars. Pharm.*, 2005; 46: 5-18.
- Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E and Yildirim Z. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. *J. Appl. Toxicol.*, 2004; 24: 27-35.
- Elchuri. CuZnSOD deficiency leads to persistent and wide spread oxidative damage and hepato carcinogenesis later in life. *Oncogenes*, 2005; 24: 367-380.
- Halliwell B. *Biochem. Pharmacol.*, 1995; 49: 1341-1348.
- Sakr SA and El-abd SF. Selenium induced oxidative stress, histological and histochemical alterations in testis of albino rat. *Ozean J. Appl. Sci.*, 2009; 2: 1943-2429.

31. Antunes LMG and Darin DJC. Effects of antioxidants curcumin or selenium on cisplatin induced nephrotoxicity and lipid peroxidation in rats. *Pharmacol. Res.*, 2001; 43: 145-150.
32. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M and Akyol O. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. *Pharmacol. Res.*, 2003; 47: 149-156.
33. Ather MA and Ronald D. The automated thios micarbazide-diacetyly monoxime method for plasma urea. *Clin. Chem.*, 1969; 97: 16393-16396.
34. Vannelli TA, Dykman A and Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. *J. Biol. Chem.*, 2002; 277: 12824-12829.
35. Duque I, Garcia-Escribano C, Rodriguez-Puyol M. and Diez-Marques ML. Effects of reactive oxygen species on cultured rat mesangial cells and isolated rat glomeruli. *Am. J. Physiol.*, 1992; 263: 466-473.
36. Combs GF Jr. and Gray WP. Chemopreventive agents: Selenium. *Pharmacol. Ther.*, 1998; 79: 179-192.